These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37483328)

  • 1. Health Care Resource Use and Social Costs in Mild Cognitive Impairment and Mild Alzheimer's Disease.
    Takechi H; Yoshino H
    J Alzheimers Dis Rep; 2023; 7(1):731-738. PubMed ID: 37483328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic and caregiver impact of Alzheimer's disease across the disease spectrum: a cohort study.
    Dauphinot V; Potashman M; Levitchi-Benea M; Su R; Rubino I; Krolak-Salmon P
    Alzheimers Res Ther; 2022 Feb; 14(1):34. PubMed ID: 35151368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2022 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2022 Apr; 18(4):700-789. PubMed ID: 35289055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
    Robinson RL; Rentz DM; Andrews JS; Zagar A; Kim Y; Bruemmer V; Schwartz RL; Ye W; Fillit HM
    J Alzheimers Dis; 2020; 75(2):437-450. PubMed ID: 32250304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study.
    Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Matsumura T; Meguro K; Yamada M; Mimura M; Arai H; Treuer T
    Curr Med Res Opin; 2021 Aug; 37(8):1331-1339. PubMed ID: 33904362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives of patients, care partners, and primary care physicians on management of mild cognitive impairment and mild Alzheimer's disease dementia.
    Brunton S; Pruzin JJ; Alford S; Hamersky C; Sabharwal A; Gopalakrishna G
    Postgrad Med; 2023 Jun; 135(5):530-538. PubMed ID: 37219410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
    Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
    Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease progression and costs at the 3-year follow-up of the GERAS-US study.
    Chandler JM; Rentz DM; Zagar A; Kim Y; Schwartz RL; Fillit H
    Alzheimers Dement (Amst); 2023; 15(2):e12430. PubMed ID: 37091310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the Pan-European Economic Burden of Alzheimer's Disease.
    Martins R; Urbich M; Brännvall K; Gianinazzi M; Ching JE; Khoury CP; El-Hayek YH
    JAR Life; 2022; 11():38-46. PubMed ID: 36923231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
    Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
    Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.
    Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Treuer T; Sato M; Kahle-Wrobleski K; Meguro K; Yamada M; Mimura M; Arai H
    J Alzheimers Dis; 2020; 74(1):127-138. PubMed ID: 31985460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of dependence and function on costs of care for Alzheimer's disease and mild cognitive impairment in Ireland.
    Gillespie P; O'Shea E; Cullinan J; Lacey L; Gallagher D; Ni Mhaolain A;
    Int J Geriatr Psychiatry; 2013 Mar; 28(3):256-64. PubMed ID: 23386588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain.
    Darbà J; Kaskens L
    Clinicoecon Outcomes Res; 2015; 7():387-95. PubMed ID: 26170703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2023 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2023 Apr; 19(4):1598-1695. PubMed ID: 36918389
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.